Table 3

Biological and diagnosis tests of patients with confirmed AHF syndrome

All patients with AHF
(n=507)
Group 1
(n=335)
Group 2
(n=172)
P value
Biological analysis
 Performed507 (100%)335 (100%)172 (100%)
 Sodium, mmol/L138 (135; 141)138 (135; 141)139 (135; 141)0.40
 Potassium, mmol/L4 (4, 5)4 (4, 5)4 (4, 5)0.89
 Creatinine clearance, mL/min50 (35; 69.05)40 (29; 49.9)78.5 (67; 91)<0.01
 Creatinine clearance <30 mL/min89 (17.55%)89 (26.57%)0 (0%)<0.01
 Haemoglobin, g/L130 (110, 140)120 (110, 130)130 (130, 140)0.06
 Troponin positive271 (53.45%)195 (58.21%)76 (44.19%)<0.01
 BNP, ng/L991 (507.5; 2443.5)1157.5 (569.25; 2680.5)534 (291; 1292)<0.01
 Pro-BNP, ng/L4025 (1729; 8863)5120 (2520; 12 399.75)2513 (1146.5; 5376.5)<0.01
ECG
 Performed500 (98.61%)329 (98.20%)171 (99.41%)
 Sinusal220 (44%)145 (43.28%)75 (43.6%)0.92
 Atrial fibrillation213 (42.01)139 (41.49%)74 (43.02%)1.00
 Driven44 (8.8%)33 (9.85%)11 (6.4%)0.19
 AVB21 (4.14%)14 (4.18%)7 (4.07%)0.86
 LBBB86 (17.2%)64 (19.1%)22 (12.79%)<0.05
 RBBB59 (11.8%)34 (10.15%)25 (14.53%)0.43
 Repolarisation disorder101 (20.2%)73 (21.79%)28 (16.28%)0.09
Chest X-ray
 Performed481 (94.87%)318 (94.92%)163 (94.76%)
 Normal24 (4.73%)11 (3.28%)13 (7.56%)0.20
 Cardiomegaly235 (48.86%)171 (51.04%)64 (37.21%)0.01
 Interstitial opacities284 (59.04%)202 (60.3%)82 (47.67%)0.02
 Alveolar opacities108 (22.45%)64 (19.1%)44 (25.58%)0.05
  • Data are median (IQR) mmol/L, median (IQR) mL/min, median (IQR) g/dL, median (IQR) ng/L or number (%) of patients.

  • Group 1: patients with CRS; group 2: patients with normal renal function.

  • AHF, acute heart failure; AVB, atrioventricular block; BNP, brain natriuretic peptide; CRS, cardiorenal syndrome; LBBB, left bundle branch block; RBBB, right bundle branch block.